Research programme: Src kinase inhibitors - Athenex

Drug Profile

Research programme: Src kinase inhibitors - Athenex

Alternative Names: KX-2377

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex
  • Class Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Sensorineural hearing loss

Most Recent Events

  • 23 Jul 2007 US FDA approves IND application for KX2 391 in patients with solid tumours or lymphoma
  • 25 Jun 2007 Kinex Pharmaceuticals files an IND with the US FDA for a phase I trial of KX2 391 in patients with solid tumours or lymphoma
  • 16 Feb 2007 Early research is ongoing for sensorineural hearing loss, osteoporosis and myocardial ischaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top